[go: up one dir, main page]

LT3250575T - N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska - Google Patents

N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska

Info

Publication number
LT3250575T
LT3250575T LTEP16702654.1T LT16702654T LT3250575T LT 3250575 T LT3250575 T LT 3250575T LT 16702654 T LT16702654 T LT 16702654T LT 3250575 T LT3250575 T LT 3250575T
Authority
LT
Lithuania
Prior art keywords
tetrahydropyrrolo
fluoropyrimidin
thiazin
pyrazine
carboxamide
Prior art date
Application number
LTEP16702654.1T
Other languages
English (en)
Inventor
David Andrew Coates
Craig Daniel WOLFANGEL
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT3250575T publication Critical patent/LT3250575T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP16702654.1T 2015-01-30 2016-01-22 N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska LT3250575T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562109733P 2015-01-30 2015-01-30
PCT/US2016/014423 WO2016122968A1 (en) 2015-01-30 2016-01-22 Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

Publications (1)

Publication Number Publication Date
LT3250575T true LT3250575T (lt) 2020-02-10

Family

ID=55275232

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16702654.1T LT3250575T (lt) 2015-01-30 2016-01-22 N-[3-[(4ar,7as)-2-amino-6-(5-fluorpirimidin-2-il)-4,4a,5,7-tetrahidropirolo[3,4-d][1,3]tiazin-7a-il]-4-fluor-fenil]-5-metoksi-pirazin-2-karboksamido tozilato druska

Country Status (41)

Country Link
US (1) US10080758B2 (lt)
EP (1) EP3250575B1 (lt)
JP (2) JP6723250B2 (lt)
KR (1) KR101950129B1 (lt)
CN (1) CN107108657B (lt)
AR (1) AR103406A1 (lt)
AU (1) AU2016211827B2 (lt)
BR (1) BR112017012149A2 (lt)
CA (1) CA2969475C (lt)
CL (1) CL2017001899A1 (lt)
CO (1) CO2017007810A2 (lt)
CR (1) CR20170287A (lt)
CY (1) CY1122548T1 (lt)
DK (1) DK3250575T3 (lt)
DO (1) DOP2017000159A (lt)
EA (1) EA031330B1 (lt)
EC (1) ECSP17048768A (lt)
ES (1) ES2768782T3 (lt)
GT (1) GT201700166A (lt)
HR (1) HRP20192240T1 (lt)
HU (1) HUE048029T2 (lt)
IL (1) IL252754A0 (lt)
LT (1) LT3250575T (lt)
MA (1) MA41420B1 (lt)
MD (1) MD3250575T2 (lt)
ME (1) ME03581B (lt)
MX (1) MX2017009713A (lt)
NZ (1) NZ732381A (lt)
PE (1) PE20171333A1 (lt)
PH (1) PH12017501356A1 (lt)
PL (1) PL3250575T3 (lt)
PT (1) PT3250575T (lt)
RS (1) RS59730B1 (lt)
SG (1) SG11201706038PA (lt)
SI (1) SI3250575T1 (lt)
SV (1) SV2017005478A (lt)
TN (1) TN2017000332A1 (lt)
TW (1) TWI574969B (lt)
UA (1) UA119581C2 (lt)
WO (1) WO2016122968A1 (lt)
ZA (1) ZA201703937B (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
CA2708043C (en) * 2007-12-07 2012-11-13 Pfizer Inc. Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
PE20091438A1 (es) * 2008-01-18 2009-09-26 Eisai Randd Man Co Ltd Derivados fusionados de aminodihidrotiazina
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato

Also Published As

Publication number Publication date
UA119581C2 (uk) 2019-07-10
WO2016122968A1 (en) 2016-08-04
US20170368071A1 (en) 2017-12-28
PH12017501356A1 (en) 2017-12-11
ME03581B (me) 2020-07-20
EP3250575A1 (en) 2017-12-06
PT3250575T (pt) 2020-01-16
US10080758B2 (en) 2018-09-25
AU2016211827B2 (en) 2018-04-26
MX2017009713A (es) 2017-11-17
CA2969475A1 (en) 2016-08-04
TN2017000332A1 (en) 2019-01-16
ZA201703937B (en) 2019-01-30
KR101950129B1 (ko) 2019-02-19
AR103406A1 (es) 2017-05-10
CO2017007810A2 (es) 2017-10-20
GT201700166A (es) 2018-11-23
SG11201706038PA (en) 2017-08-30
CN107108657B (zh) 2021-10-08
HRP20192240T1 (hr) 2020-03-06
BR112017012149A2 (pt) 2018-01-02
MD3250575T2 (ro) 2020-03-31
MA41420B1 (fr) 2020-02-28
TW201636354A (zh) 2016-10-16
RS59730B1 (sr) 2020-02-28
PE20171333A1 (es) 2017-09-13
CY1122548T1 (el) 2021-01-27
ECSP17048768A (es) 2017-11-30
SI3250575T1 (sl) 2019-12-31
KR20170097782A (ko) 2017-08-28
SV2017005478A (es) 2018-02-09
JP2019142902A (ja) 2019-08-29
CA2969475C (en) 2019-06-18
HUE048029T2 (hu) 2020-05-28
EP3250575B1 (en) 2019-11-20
IL252754A0 (en) 2017-08-31
EA031330B1 (ru) 2018-12-28
JP2018503666A (ja) 2018-02-08
DK3250575T3 (da) 2020-01-20
AU2016211827A1 (en) 2017-06-22
EA201791229A1 (ru) 2017-11-30
PL3250575T3 (pl) 2020-06-01
NZ732381A (en) 2018-05-25
JP6723250B2 (ja) 2020-07-15
DOP2017000159A (es) 2017-07-31
ES2768782T3 (es) 2020-06-23
TWI574969B (zh) 2017-03-21
CR20170287A (es) 2017-07-20
CL2017001899A1 (es) 2018-03-23
CN107108657A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
IL264092A (en) 1, 3-dihydroxy-phenyl derivatives are useful as immunomodulators
ZA201708417B (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
ZA201900506B (en) Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides
IL260011A (en) History of 5,3-diphenyl-diazole water-soluble compounds
ZA201708769B (en) Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one
LT3230289T (lt) 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
EP3390368A4 (en) PROCESS FOR PREPARING SUBSTITUTED 5,6-DIHYDRO-6-PHENYL BENZO [F] ISOCHINOLINE-2-AMINE
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
SI3274331T1 (sl) Izdelava 4,5,6,7-tetrahidroizozaksolo (5,4-C)piridin-3-ol
IL259556A (en) Solid forms of substituted 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine compounds
IL275126B (en) Methods for predicting the progression of Barrett's esophagus
GB2561089B (en) Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one
ZA201703937B (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
EP3277275A4 (en) Processes for the preparation of 2-thiophenecarbonyl chloride
HK1241377A1 (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
HUP1500451A2 (en) Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates
MA45184A (fr) Procédé de préparation de l'éluxadoline .
GB2533003B (en) An over-garment comprising means for detachably affixing the over-garment to the waistband or belt of an item of apparel located inside it.
GB201512065D0 (en) Platin pleasure